NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional) | RFA DA 22 036

Opportunity Information: Apply for RFA DA 22 036

The NIH HEAL Initiative funding opportunity (RFA-DA-22-036) is an R01 grant program led by the National Institute on Drug Abuse (NIDA) in collaboration with other NIH Institutes, Centers, and Offices. It sits within the broader HEAL (Helping to End Addiction Long-term) Initiative, launched in 2018 to accelerate research-based solutions to the opioid crisis in the United States. This specific call supports research projects that develop and rigorously test multi-level interventions aimed at preventing opioid misuse and opioid use disorder (OUD), while also addressing co-occurring conditions that often travel with opioid-related risk, such as mental health disorders, suicidality, and potentially other substance use and substance-related outcomes. Clinical trials are optional, meaning applicants can propose trials if appropriate, but they are not required to do so.

A central feature of the opportunity is its focus on intervening on social determinants of health (SDOH). NIH is looking for interventions that do not just target individuals, but also address modifiable social and structural factors shaping risk, protection, access to care, and long-term outcomes. In practice, that means proposals should be grounded in theory and designed to operate at multiple levels (for example, individual, family, school, healthcare system, workplace, community, policy, or other local systems). The goal is to build an evidence base for strategies that change the broader social context in ways that reduce the likelihood of opioid misuse and OUD before they occur, especially in populations and subgroups disproportionately affected by the opioid crisis.

Health equity is not treated as a side benefit; it is a core requirement. Applications must explicitly aim to reduce health inequities in a U.S. population or subgroup impacted by the opioid epidemic. This includes designing interventions and evaluations that are relevant to communities facing disproportionate exposure to risk factors (like economic instability, housing insecurity, limited access to prevention and behavioral health care, criminal justice involvement, stigma, and other structural barriers). Proposals are expected to show a clear rationale for why the selected SDOH targets are important, malleable, and connected to opioid misuse risk and co-occurring conditions in the chosen population.

NIH also emphasizes that projects must go beyond measuring whether an intervention works by examining how and why it works. Applicants are expected to study mechanisms of action, meaning the pathways through which the intervention produces effects (for example, changes in stress, social support, service access, school engagement, economic stability, exposure to drug markets, or other mediators). Alongside effectiveness and mechanism testing, the research must include economic analyses to help decision-makers understand real-world adoption considerations, such as cost, cost-effectiveness, return on investment, budget impact, or implementation resource requirements. This is meant to ensure that positive findings can translate into practical choices by health systems, community organizations, and policymakers.

Another strong theme is scalability and sustainability. NIH is encouraging interventions that can realistically be maintained over time and expanded to broader settings if proven effective. That typically implies attention to implementation feasibility, staffing needs, community buy-in, compatibility with existing systems, and the ability to deliver the intervention under real-world constraints. While the announcement text highlights the need for sustainable, scalable approaches, applicants would generally be expected to reflect those priorities in their design choices, partnerships, and evaluation plans.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The opportunity also specifically calls out additional eligible applicant categories such as faith-based or community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as U.S. territories or possessions and certain regional organizations and eligible federal agencies.

At the same time, NIH makes clear that foreign involvement is restricted. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed. In short, the work is intended to be U.S.-focused and U.S.-based, aligned with the goal of addressing the opioid crisis domestically.

From the source details provided, the opportunity is categorized as a discretionary grant in the health and education funding activity area, associated with CFDA numbers 93.242, 93.279, and 93.866. The original closing date listed is March 2, 2022, with a creation date of November 16, 2021. An award ceiling is not specified in the provided data, and the expected number of awards is not listed here. Overall, this R01 opportunity supports rigorous, theory-driven, multi-level prevention research that targets social determinants to reduce opioid misuse/OUD and co-occurring conditions, with a strong emphasis on health equity, understanding mechanisms, and producing economic evidence that can guide adoption and scale-up.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.279, 93.866.
• This funding opportunity was created on 2021-11-16.
• Applicants must submit their applications by 2022-03-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 22 036

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: